Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
17 janv. 2025 07h11 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial...
Novo Nordisk A/S - share repurchase programme
13 janv. 2025 08h52 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
08 janv. 2025 06h30 HE
|
Novo Nordisk A/S
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular...
Novo Nordisk A/S - share repurchase programme
20 déc. 2024 07h47 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
20 déc. 2024 05h41 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial...
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
18 déc. 2024 08h59 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’...
Novo Nordisk A/S - share repurchase programme
16 déc. 2024 07h52 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
16 déc. 2024 01h29 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks...
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
14 déc. 2024 00h08 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of...
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
12 déc. 2024 08h47 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for...